4DMedical receives $6.0m R&D Tax Incentive
| Stock | 4DMEDICAL Ltd (4DX.ASX) |
|---|---|
| Release Time | 2 Sep 2025, 9:38 a.m. |
| Price Sensitive | Yes |
4DMedical receives $6.0m R&D Tax Incentive
- 4DMedical extends cash runway with $6.0 million R&D Tax Incentive
- Potential capital injection of up to $22.7 million from exercise of 41 million options
- XV LVAS® technology breakthrough published in leading respiratory journal
4DMedical Limited, a global leader in respiratory imaging technology, has announced the receipt of $6.0 million in Research and Development (R&D) Tax Incentive credits. This, combined with the recently announced $10.0 million strategic investment from Pro Medicus, has bolstered the company's proforma cash balance as of June 30, 2025, to $22.9 million. Additionally, the potential exercise of approximately 41 million options (ASX:4DXOA), with an expiry date of October 1 and an exercise price of $0.55, could further inject up to $22.7 million into the company's cash balance. With this enhanced financial position, 4DMedical is well-positioned to execute the rollout of its CT:VQ™ solution and continue the commercialization of its existing product suite. The company has also announced the publication of a study in the American Journal of Respiratory and Critical Care Medicine, one of the world's leading respiratory medicine journals. The study details the unique functional insights delivered by 4DMedical's XV LVAS® technology, which can predict post-procedural complications in interventional procedures that are otherwise unavailable with conventional imaging. This breakthrough has the potential to improve patient outcomes and reduce the burden of complications for healthcare systems.
With the additional capital from the R&D Tax Incentive and the potential exercise of options, 4DMedical is well-positioned to execute the rollout of its CT:VQ™ solution and continue the commercialization of its existing product suite.
4DMedical remains focused on its mission to deliver world-class diagnostic tools globally, with a particular emphasis on COPD, a leading cause of death. The company's technology, including the XV LVAS® solution, has the potential to significantly improve patient management and reduce the burden of complications in respiratory care.